AdvaMed Distances Devices From Proposed Postmarket Surveillance Reforms
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed is continuing to draw attention to essential differences between medical device and drug postmarket regulation as FDA faces increased public scrutiny related to drug recalls
You may also be interested in...
Devices Paroled, Not Unconditionally, From Hill’s Drug Safety Hearings
House Energy & Commerce and Senate HELP staffers differ slightly in their perceptions of medical device applicability to drug safety concerns, which are the preeminent FDA issue for the 109th Congress
Devices Paroled, Not Unconditionally, From Hill’s Drug Safety Hearings
House Energy & Commerce and Senate HELP staffers differ slightly in their perceptions of medical device applicability to drug safety concerns, which are the preeminent FDA issue for the 109th Congress
In Critical Climate, Leavitt Pledges to Maintain FDA “Brand” Integrity
HHS Secretary-nominee Michael Leavitt vowed to uphold the trustworthiness of the FDA "brand" in Jan. 18 testimony before the Senate HELP Committee